AnaptysBio Balance Sheet Health
Financial Health criteria checks 5/6
AnaptysBio has a total shareholder equity of $84.4M and total debt of $350.6M, which brings its debt-to-equity ratio to 415.5%. Its total assets and total liabilities are $493.4M and $409.1M respectively.
Key information
415.5%
Debt to equity ratio
US$350.56m
Debt
| Interest coverage ratio | n/a |
| Cash | US$430.12m |
| Equity | US$84.37m |
| Total liabilities | US$409.05m |
| Total assets | US$493.42m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AN6's short term assets ($448.7M) exceed its short term liabilities ($43.9M).
Long Term Liabilities: AN6's short term assets ($448.7M) exceed its long term liabilities ($365.2M).
Debt to Equity History and Analysis
Debt Level: AN6 has more cash than its total debt.
Reducing Debt: AN6's debt to equity ratio has increased from 0.7% to 415.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AN6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AN6 has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 17% each year.